Cochrane · systematic review · CD010676
Antidepressants versus placebo for panic disorder in adults
Bighelli, I, Castellazzi, M, Cipriani, A, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
Common Mental DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
28
current version
GRADE rated
24
No studies
4
Included studies
NR
No studies 4 · 14.3%Ungraded 0 · 0%Very low 1 · 3.6%Low 6 · 21.4%Moderate 15 · 53.6%High 2 · 7.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Antidepressants compared to placebo for panic disorder
Population: adults with panic disorder
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes (2‐6 months post‐treatment) Antidepressants vs placebo | no estimate extracted | NR | No studies |
Failure to respond Antidepressants vs placebo | RR 0.72 [0.66, 0.79] | 30 studies · 6500 participants | Low Downgraded: risk of bias, inconsistency |
Total number of dropouts Antidepressants vs placebo | RR 0.88 [0.81, 0.97] | 38 studies · 7850 participants | Moderate Downgraded: risk of bias |
Failure to remit Antidepressants vs placebo | RR 0.83 [0.78, 0.88] | 24 studies · 6164 participants | Moderate Downgraded: risk of bias |
Panic symptoms ‐ endpoint score (various scales) Antidepressants vs placebo | no estimate extracted | 15 studies · 3699 participants | Low Downgraded: risk of bias, inconsistency |
Panic symptoms ‐ mean change (various scales) Antidepressants vs placebo | no estimate extracted | 10 studies · 2010 participants | Low Downgraded: risk of bias, inconsistency |
Number of dropouts due to adverse effects Antidepressants vs placebo | RR 1.49 [1.25, 1.78] | 33 studies · 7688 participants | Moderate Downgraded: risk of bias |
Tricyclic antidepressants compared to placebo for panic disorder
Population: adults with panic disorder
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes (2‐6 months post‐treatment) Tricyclic antidepressants vs placebo | no estimate extracted | NR | No studies |
Failure to respond Tricyclic antidepressants vs placebo | RR 0.73 [0.63, 0.86] | 9 studies · 829 participants | Moderate Downgraded: risk of bias |
Total number of dropouts Tricyclic antidepressants vs placebo | RR 0.74 [0.63, 0.86] | 17 studies · 1906 participants | Moderate Downgraded: risk of bias |
Failure to remit Tricyclic antidepressants vs placebo | RR 0.82 [0.69, 0.99] | 8 studies · 1294 participants | Low Downgraded: risk of bias, inconsistency |
Panic symptoms ‐ endpoint score (various scales) Tricyclic antidepressants vs placebo | no estimate extracted | 7 studies · 1247 participants | Moderate Downgraded: risk of bias |
Panic symptoms ‐ mean change (various scales) Tricyclic antidepressants vs placebo | no estimate extracted | 2 studies · 70 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Number of dropouts due to adverse effects Tricyclic antidepressants vs placebo | RR 1.97 [1.33, 2.91] | 10 studies · 1641 participants | Moderate Downgraded: risk of bias |
Selective serotonin reuptake inhibitors compared to placebo for panic disorder
Population: adults with panic disorder
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes (2‐6 months post‐treatment) Selective serotonin reuptake inhibitors vs placebo | no estimate extracted | NR | No studies |
Failure to respond Selective serotonin reuptake inhibitors vs placebo | RR 0.75 [0.67, 0.84] | 21 studies · 4000 participants | Low Downgraded: risk of bias, inconsistency |
Total number of dropouts Selective serotonin reuptake inhibitors vs placebo | RR 0.99 [0.9, 1.09] | 23 studies · 4302 participants | Moderate Downgraded: risk of bias |
Failure to remit Selective serotonin reuptake inhibitors vs placebo | RR 0.81 [0.75, 0.88] | 16 studies · 3339 participants | Moderate Downgraded: risk of bias |
Panic symptoms ‐ endpoint score (various scales) Selective serotonin reuptake inhibitors vs placebo | no estimate extracted | 6 studies · 1625 participants | Moderate Downgraded: risk of bias |
Panic symptoms ‐ mean change (various scales) Selective serotonin reuptake inhibitors vs placebo | no estimate extracted | 7 studies · 1255 participants | Moderate Downgraded: risk of bias |
Number of dropouts due to adverse effects Selective serotonin reuptake inhibitors vs placebo | RR 1.45 [1.16, 1.81] | 22 studies · 4131 participants | Moderate Downgraded: risk of bias |
Serotonin‐norepinephrine reuptake inhibitors compared to placebo for panic disorder
Population: adults with panic disorder
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes (2‐6 months post‐treatment) Serotonin‐norepinephrine reuptake inhibitors vs placebo | no estimate extracted | NR | No studies |
Failure to respond Serotonin‐norepinephrine reuptake inhibitors vs placebo | RR 0.61 [0.41, 0.91] | 4 studies · 1531 participants | Low Downgraded: inconsistency |
Total number of dropouts Serotonin‐norepinephrine reuptake inhibitors vs placebo | RR 0.93 [0.69, 1.26] | 4 studies · 1531 participants | Moderate Downgraded: inconsistency |
Failure to remit Serotonin‐norepinephrine reuptake inhibitors vs placebo | RR 0.84 [0.75, 0.95] | 4 studies · 1531 participants | Moderate Downgraded: inconsistency |
Panic symptoms ‐ endpoint score (various scales) Serotonin‐norepinephrine reuptake inhibitors vs placebo | no estimate extracted | 2 studies · 723 participants | High |
Panic symptoms ‐ mean change (various scales) Serotonin‐norepinephrine reuptake inhibitors vs placebo | no estimate extracted | 2 studies · 685 participants | High |
Number of dropouts due to adverse effects Serotonin‐norepinephrine reuptake inhibitors vs placebo | RR 1.49 [0.92, 2.4] | 4 studies · 1531 participants | Moderate Downgraded: imprecision |